VPIM
RARE icon

Vanguard Personalized Indexing Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,541
Closed -$271K – 1290
2022
Q2 		$271K Sell
4,541
-4,755
-51% -$293K 0.01% 1018
2022
Q1 		$675K Sell
9,296
-3,790
-29% -$264K 0.03% 668
2021
Q4 		$1.1M Buy
13,086
+6,947
+113% +$565K 0.06% 342
2021
Q3 		$554K Buy
+6,139
New +$555K 0.05% 459

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Personalized Indexing Management's RARE Position: Q3 2022 in Review

Vanguard Personalized Indexing Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 4,541 shares — an estimated $271K sold.

Vanguard Personalized Indexing Management first reported a position in RARE in Q3 2021 and held it in 4 quarters. The position peaked at $1.1M in Q4 2021. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Vanguard Personalized Indexing Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 4,541 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $271K.
  • Vanguard Personalized Indexing Management first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and held it in 4 quarters.
  • Vanguard Personalized Indexing Management's Ultragenyx Pharmaceutical position peaked at $1.1M in Q4 2021.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Vanguard Personalized Indexing Management's 13F filing for Q3 2022, filed 14 Nov 2022.